Clinical Trials
Olanzapine and Prochlorperazine Reduce Persistent Chemotherapy-Induced Nausea
Peppone et alJournal of the National Cancer Institute

In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial conducted across 23 NCORP community oncology sites between April 2018 and January 2024, researchers evaluated escalation strategies for persistent chemotherapy-induced nausea. The study enrolled women aged 18 years or older with breast cancer receiving moderately or highly emetogenic chemotherapy who reported persistent nausea, defined as a Cycle 1 nausea score of 3 or higher on a 1-to-7 scale despite guideline-consistent prophylaxis. During Cycle 2, 310 patients in the intention-to-treat population were randomized 1:1:1 to receive placebo (n = 91), prochlorperazine at 10 mg every 8 hours on Days 1 to 4 (n = 110), or olanzapine at 10 mg once daily on Days 1 to 4 (n = 109), each added to standardized antiemetic therapy consisting of netupitant/palonosetron plus dexamethasone. The trial's primary endpoint was the change in average nausea from Cycle 1 to Cycle 2, and the key secondary outcome was the change in maximum nausea. Both active escalation therapies improved average nausea compared with placebo, with a between-group difference of -0.57 (P =.001) for olanzapine and -0.44 (P =.01) for prochlorperazine. Olanzapine also reduced maximum nausea to a greater extent than prochlorperazine (difference, -0.59; P =.02). Furthermore, olanzapine improved FACT-G quality-of-life scores compared with placebo (difference, 4.91; P =.006) and prochlorperazine (difference, 5.80; P =.001). Adverse events across cohorts were predominantly grade 1 to 2, with no therapy discontinuations attributable to toxicity. The trial authors concluded that olanzapine serves as an effective escalation option, with prochlorperazine representing a viable alternative when olanzapine is not suitable.
Key Takeaways
- Addition of either olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduced average persistent nausea compared with placebo (between-group difference, -0.57, P =.001 for olanzapine; -0.44, P =.01 for prochlorperazine).
- Olanzapine achieved greater reductions in maximum nausea than prochlorperazine (difference, -0.59; P =.02) along with superior improvements in FACT-G quality-of-life scores versus placebo (difference, 4.91; P =.006) and prochlorperazine (difference, 5.80; P =.001).
- Both agents showed favorable tolerability with primarily grade 1 to 2 adverse events and no toxicity-related treatment discontinuations.
Read the original sourceJournal of the National Cancer Institute
